Gilead Sciences Q2 EPS Estimate Boosted by Zacks Research

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Zacks Research raised their Q2 2026 EPS estimates for shares of Gilead Sciences in a note issued to investors on Friday, April 4th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will earn $1.84 per share for the quarter, up from their prior forecast of $1.83. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2026 earnings at $2.29 EPS, FY2026 earnings at $8.02 EPS, Q1 2027 earnings at $1.88 EPS and FY2027 earnings at $8.62 EPS.

Several other analysts also recently commented on GILD. Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. BMO Capital Markets upped their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Oppenheimer lifted their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday, March 4th. Finally, Bank of America upped their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $105.12.

Gilead Sciences Trading Down 2.2 %

NASDAQ GILD opened at $103.19 on Monday. Gilead Sciences has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock’s fifty day moving average price is $107.84 and its 200-day moving average price is $96.31. The stock has a market cap of $128.49 billion, a P/E ratio of 278.89, a P/E/G ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a $0.79 dividend. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.06%. Gilead Sciences’s dividend payout ratio is 854.05%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 302,785 shares of company stock worth $30,503,250 in the last three months. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently made changes to their positions in the company. HHM Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership bought a new stake in Gilead Sciences in the fourth quarter worth $28,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the fourth quarter worth $29,000. Crews Bank & Trust bought a new position in Gilead Sciences during the fourth quarter valued at $31,000. Finally, Stephens Consulting LLC raised its stake in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the period. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.